Findings from a new study have demonstrated satisfactory long-term effectiveness of biologic therapies in the treatment of psoriasis in clinical practice.
The Swedish study followed 583 individuals for up to 10 years, with routine monitoring of Psoriasis Area Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol five dimensions questionnaire (EQ-5D) measurement.
Writing in the British Journal of Dermatology , the authors reported significant improvement in PASI, DLQI and EQ-5D 3-5 months after switch to biologic therapy. Improvements were sustained over the whole observation period.
Marcus Schmitt-Egenolf, professor at the Department of Public Health and Clinical Medicine at Umeå University in Sweden and senior author of the study, said the results suggest that both the real-world clinical effectiveness and quality of life benefits of biological treatment are sustained over time.
“These results may support clinicians in initiating and continuing biological treatment for patients with poor outcomes under conventional treatment. This is an important finding from an international perspective, as data on real-life long-time outcomes of biological treatment is rare but crucial for treatment guidelines,” he said.